Name drug brands in oral factor b inhibitors that have a strong history of consistent product performance over the years in united states?

Short answer: There are no FDA-approved oral Factor B inhibitors with established US brand names and a long, years-long performance history.

What exists in the space (as of 2024–2026):
- Iptacopan (LNP023) – an oral Factor B inhibitor that has been in late-stage (Phase 3) development for various complement-mediated diseases. It does not have a US-approved brand name yet.
- BCX9930 – another oral Factor B inhibitor in clinical development. Also not approved and, therefore, no US brand name.

Notes:
- Many Factor B inhibitors are still in trials, so there isn’t a brand-name product with a long-standing performance record in the US.
- If you’re looking for established, long-proven brands in the broader complement area, those would be agents targeting other parts of the pathway (for example, C5 inhibitors like Soliris/eculizumab or Ultomiris/ravulizumab, or C3 inhibitors like pegylated C3 inhibitors), rather than Factor B inhibitors.

If you want, I can:
- Update you on the latest trial statuses for iptacopan and BCX9930.
- Provide a quick map of where Factor B inhibitors stand in the US regulatory pipeline.
- List currently approved complement inhibitors with strong US performance history.